Your browser doesn't support javascript.
loading
A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
Jackson, Lisa A; Rupp, Richard; Papadimitriou, Athanasia; Wallace, Derek; Raanan, Marsha; Moss, Kelley J.
Affiliation
  • Jackson LA; Group Health Research Institute, Seattle, WA 98101, USA.
  • Rupp R; University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
  • Papadimitriou A; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon, Zurich, Switzerland. Electronic address: athanasia.papadimitriou@takeda.com.
  • Wallace D; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon, Zurich, Switzerland.
  • Raanan M; Takeda Development Center Americas Inc., Deerfield, IL 60015, USA.
  • Moss KJ; Takeda Vaccines, Inc., Cambridge, MA 02139, USA.
Vaccine ; 36(27): 3976-3983, 2018 06 22.
Article in En | MEDLINE | ID: mdl-29789238

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Virus / Dengue Vaccines / Immunogenicity, Vaccine / Antibodies, Viral Type of study: Clinical_trials / Guideline Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: Vaccine Year: 2018 Document type: Article Affiliation country: United States Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Virus / Dengue Vaccines / Immunogenicity, Vaccine / Antibodies, Viral Type of study: Clinical_trials / Guideline Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: Vaccine Year: 2018 Document type: Article Affiliation country: United States Country of publication: Netherlands